Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.44 |
| ▸ | TP53 | P04637 | 5/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | IDH2 | P48735 | 3/20 | 0.40 |
| ▸ | THRB | P10828 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 2/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3267054 | 0.83 | MAPK14 (0.42) | MAPTTP53LMNARXFP1SMN1; SMN2 | |
| SCHEMBL3266934 | 0.82 | RAB9A (0.38) | MAPTLMNAKIF11SMN1; SMN2 | |
| SCHEMBL3268217 | 0.78 | SLC2A1 (0.47) | MAPTTP53SLC2A1IDH2THRB | |
| SCHEMBL3267196 | 0.77 | TRPC5 (0.46) | MAPTTP53SMN1; SMN2 | |
| SCHEMBL10282666 | 0.76 | APP (0.64) | MAPTSLC2A1IDH2LMNAAPP | |
| SCHEMBL3271133 | 0.75 | KCNN3 (0.39) | MAPTLMNASMN1; SMN2 | |
| SCHEMBL3266446 | 0.75 | TRPC5 (0.44) | MAPTTP53SMN1; SMN2 | |
| SCHEMBL3267063 | 0.74 | NPC1 (0.43) | LMNASMN1; SMN2 | |
| SCHEMBL3267224 | 0.74 | MAPT (0.40) | MAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL1391653 | 0.73 | LMNA (0.52) | MAPTSLC2A1IDH2LMNAAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399674-B2 | Quinolines | HOFFMAN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120136018-A1 | QUINOLINES | KOLCZEWSKI SABINE (DE) | 2012-05-31 | — | — | US | disclosed |
| EP-2195296-A1 | QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-06-16 | — | — | EP | disclosed |
| US-20090088451-A1 | QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | US | disclosed |
| WO-2009040290-A1 | QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088451-A1 | QUINOLINES | HTR5A, HTR1A, HTR1E | MAPT 1853/4885TP53 4670/4885SLC2A1 2012/4885 |
| US-20120136018-A1 | QUINOLINES | HTR5A, HTR1A, HTR1E | MAPT 1853/4885TP53 4670/4885SLC2A1 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.